18
Basic
Limited
Enhanced
May discuss
maintenance
systemic
therapies (e.g.,
antiangiogenic,
targeted therapies)
for patients who
have received
surgery and prior
chemotherapy
For guidance
regarding the use of
PARPi, refer to the
ASCO guidline
a
No role for
maintenance
systemic therapy
Maintenance Systemic Therapy for Stage III/IV
Maintenance
systemic therapies
(antiangiogenic,
targeted
therapies) are not
recommended
for patients who
have received
surgery and prior
chemotherapy
Figure 4. Maintenance Systemic Therapy Recommendations
by Resource Level
a
Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
J Clin Oncol. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924
Treatment
